Mithra Pharmaceuticals SA

See all company news

• (02.Jun.2022) Exercise of a Call Option from Goldman Sachs and Additional Information on the Financing Strategy
• (13.May.2022) Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital
• (06.May.2022) Publication of a Transparency Notification Received from Glenernie Capital
• (29.Apr.2022) Publication of Transparency Notifications Received from Goldman Sachs
• (26.Apr.2022) Mithra CDMO Announces Collaboration with MedinCell for the Development of Injectable Products for Malaria and Transplant Rejection
• (20.Apr.2022) Information on the Total Number of Voting Rights (Denominator) Following Exercise of a Call Option from Goldman Sachs
• (18.Apr.2022) Mithra Announces the Extension of the Capital Commitment Agreement with LDA Capital by Two Years and the Increase of the Commitment by EUR 25 million
• (15.Apr.2022) Mithra Releases 2021 Annual Report
• (14.Apr.2022) Mithra Announces Improved Consolidated Topline Results from Donesta® Phase 3 Studies and Launch of Recruitment for the Extension of European Study
• (08.Apr.2022) Publication of a Transparency Notification Received from Goldman Sachs
• (29.Mar.2022) Publication of a Transparency Notification Received from FrançOis Fornieri
• (29.Mar.2022) Publication of a Transparency Notification Received from Goldman Sachs
• (23.Mar.2022) Publication of a Transparency Notification Received from Goldman Sachs
• (21.Mar.2022) Exercise of a Second Drawing Request Under Equity Funding Agreement with Goldman Sachs
• (08.Mar.2022) Mithra Reports Full Year 2021 Financial Results
• (28.Feb.2022) Publication of a Transparency Notification Received from FrançOis Fornieri
• (25.Feb.2022) Publication of a Transparency Notification Received from Goldman Sachs
• (25.Feb.2022) Publication of a Transparency Notification Received from Alychlo
• (16.Feb.2022) Publication of a Transparency Notification Received from FrançOis Fornieri
• (16.Feb.2022) Mithra and Searchlight Pharma Announce Launch of Haloette in Canada
• (14.Feb.2022) Information on the Total Number of Voting Rights (Denominator) Following the Completion of the LDA Capital Increase
• (07.Feb.2022) Mithra Obtains Equity Funding for up to EUR 100 Million
• (14.Jan.2022) Mithra Announces Positive Top-Line Results from Donesta Phase 3 Studies in Menopausal Women
• (10.Jan.2022) Publication of a Transparency Notification Received from FrançOis Fornieri
• (01.Jan.2022) European Urology Today, the Official Newsletter of the European Association of Urology, Publishes the Results of the PCombi Study
• (20.Dec.2021) Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital
• (29.Nov.2021) MAYNE PHARMA AND MITHRA ANNOUNCE TGA APPROVAL OF NEXTSTELLIS® ORAL CONTRACEPTIVE
• (10.Nov.2021) Information on the Total Number of Voting Rights (Denominator) Following the Completion of the LDA Capital Increase
• (21.Oct.2021) Mithra Announces Estelle® Launch in Belgium
• (15.Oct.2021) The Board of Directors confirms Leon Van Rompay as Mithra’s CEO
• (06.Oct.2021) Mithra Provides FDA Update on Myring®
• (24.Sep.2021) Mithra Announces 2021 Half Year Results
• (24.Sep.2021) Mithra Announces Topline Results for COVID-19 Phase II Study
• (21.Sep.2021) Donesta Phase III: Recruitment Completion of American Study and Additional Recruitment in the European Study
• (21.Sep.2021) Mithra Announces an Update on PeriNesta®
• (16.Sep.2021) Mithra Announces Estelle Approval in Russia
• (15.Sep.2021) Mithra and Searchlight Pharma Announce Availability of Nextstellis in Pharmacies Across Canada
• (03.Aug.2021) Initiation of Phase III Clinical Trials for the Developed Product (FSN-013) in Japan
• (15.Jul.2021) ExeVir and Mithra Announce Manufacturing Collaboration for Innovative Covid-19 Treatments
• (02.Jul.2021) Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital